SOURCE: Synergetics USA, Inc.

Synergetics USA, Inc.

March 10, 2015 16:05 ET

Synergetics Reports Second Quarter of Fiscal Year 2015 Results

O'FALLON, MO--(Marketwired - Mar 10, 2015) - Synergetics USA, Inc. (NASDAQ: SURG), a medical device company that designs, manufactures, and markets innovative surgical devices for ophthalmic and neurosurgical applications, today announced results for the second quarter of fiscal year 2015. 

Second Quarter Summary:

  • Total sales were $18.2 million, an increase of 20.5% year-over-year. Excluding the impacts of the acquisition of Sterimedix in the period, total sales increased 13.4% year-over-year.
  • Ophthalmic sales increased 8.9% year-over-year and neurosurgery sales increased 36.4% year-over-year.
  • Domestic sales increased 16.6% and International sales increased 31.0% year-over-year. International sales increased 36.8% year-over-year on a constant currency basis.
  • Disposable product sales increased 18.0% and capital equipment sales increased 44.9%.
  • GAAP EPS was $0.04 compared to a loss of $0.01 in the second quarter last year.
  • Non-GAAP EPS was $0.07 compared to $0.00 in the second quarter last year.
  • EBITDA increased 1,501.7% to $1.9 million, compared to $0.1 million last year. 

"We are very pleased with our second quarter sales performance. We reported strong organic revenue growth of 13.4% year-over-year, and our total revenue growth exceeded 20% year-over-year including the partial-period contributions from our acquisition of Sterimedix Limited," said David M. Hable, the Company's President and Chief Executive Officer. "We continue to be encouraged by the progress we are making in the commercialization of the VersaVIT 2.0 system -- the largest organic growth driver of our ophthalmic business in the second quarter -- and our valuable relationships with our OEM customers continued to pay dividends this quarter as better-than-expected demand for our disposables and capital equipment drove strong sales growth compared to last year. Synergetics' performance over the first six-months of fiscal year 2015 has been very strong with sales up 13.7% year-over-year, operating profit up 132.1% and cash flow from operations of $4.8 million. We expect continued strength in our operating and financial results over the balance of fiscal 2015."

Second Quarter Results

Second quarter of fiscal 2015 sales totaled $18.2 million, an increase of 20.5%, compared to sales of $15.1 million in the second quarter of fiscal 2014. Total sales included contributions from our acquisition of Sterimedix Limited of $1.1 million, attributable to the period of December 10, 2014 to January 31, 2015. Second quarter sales performance was driven primarily by a 36.4% increase in Neurosurgery sales and an 8.9% increase in ophthalmic sales. Other sales increased 116.8% year-over-year.

Following the completion of the acquisition of Sterimedix, the Company assessed its sales presentation format and determined that a more comprehensive breakdown of its ophthalmic and neurosurgery sales is appropriate to more completely describe its revenues by market, as compared to reporting revenues by distribution category. The following table presents the Company's revised presentation of reporting enterprise-wide sales by market, as well as the previous presentation of reporting revenues by distribution category. The Company will provide sales results under both presentation formats for the balance of fiscal 2015 and will transition to the new presentation format of sales based upon market thereafter.

                           
($'s in thousands) Three Months Ended January 31, 2015   Three Months Ended January 31, 2014   % Change y/y     Six Months Ended January 31, 2015   Six Months Ended January 31, 2014   % Change y/y  
Net Sales: Presentation based upon market  
  Ophthalmic (1) $ 9,985   $ 9,165   8.9 %   $ 19,510   $ 18,129   7.6 %
  Neurosurgery (2)   7,894     5,788   36.4 %     14,912     12,245   21.8 %
  Other (3)   310     143   116.8 %     414     252   64.3 %
  Total: $ 18,189   $ 15,096   20.5 %   $ 34,836   $ 30,626   13.7 %
   
Net Sales: Presentation based upon distribution  
Ophthalmic(4) $ 8,228   $ 8,739   (5.8 %)   $ 16,958   $ 17,237   (1.6 %)
OEM (5)   9,784     6,123   59.8 %     17,470     12,971   34.7 %
Other (6)   177     234   (24.4 %)     408     418   (2.4 %)
Total: $ 18,189   $ 15,096   20.5 %   $ 34,836   $ 30,626   13.7 %
  • Total ophthalmic sales increased 8.9% to $10.0 million, compared to $9.2 million in the second quarter of fiscal 2014. Domestic ophthalmic sales decreased 5.0% primarily due to declines in our base ophthalmic business offset, partially, by sales of VersaVIT™ and procedural kits. International ophthalmic sales increased 27.2% year-over-year primarily due to the addition of Sterimedix sales from December 10, 2014 through January 31, 2015, partially offset by a 4.3% decrease in international ophthalmology direct and distributor sales, primarily due to foreign currency adjustments.

  • Total neurosurgery sales increased 36.4% to $7.9 million, compared to $5.8 million in the second quarter of fiscal 2014. The increase in neurosurgery sales benefited primarily from strong volumes of disposable products and generators sold to Codman and Stryker compared to last year. Other sales increased 116.8% to $310,000, compared to $143,000 last year, primarily due to the addition of Sterimedix aesthetics sales from December 10, 2014 through January 31, 2015. 

  • Total domestic sales increased 16.6% to $12.9 million in the second quarter of fiscal 2015, driven by higher neurosurgery sales, which are recorded as Domestic sales, partially offset by a 5.0% decline in domestic ophthalmic sales compared to last year. International sales increased 31.0% to $5.3 million primarily due to the addition of Sterimedix sales December 10, 2014 through January 31, 2015, partially offset by the 4.3% decrease in international ophthalmology sales related to the impacts of foreign currency exchange in the period.

  • Capital equipment sales increased 44.9% to $2.3 million, or 12.9% of sales in the second quarter of fiscal 2015 compared to $1.6 million, or 10.7% of sales, in the second quarter of fiscal 2014. Disposable product sales increased 18.0% to $15.5 million, or 85.4% of sales this year, compared to sales of $13.2 million, or 87.2% of sales in the second quarter of fiscal 2014. 

Gross profit for the second quarter of fiscal 2015 totaled $9.6 million, or 52.7% of sales, compared to $8.4 million, or 55.6% of sales, in the second quarter of fiscal 2014. Year-over-year gross margin performance was driven by a product mix shift to neurosurgical sales from ophthalmic sales compared to last year, costs related to our final production at the King of Prussia facility, foreign currency exchange and inventory purchase price allocation related to our acquisition of Sterimedix.

Total operating expenses decreased 4.4% year-over-year to $8.4 million, or 46.1% of sales, in the second quarter of fiscal 2015 from $8.8 million, or 58.1% of sales, in the comparable 2014 period. Research and development expenses decreased 32.1% to $1.0 million, or 5.7% of sales, compared to 10.0% of sales last year. Sales and marketing expenses increased 0.4% to $3.6 million, or 20.0% of sales, compared to 24.0% of sales last year. General and administrative expenses decreased 2.0% to $2.9 million, or 16.2% of sales, compared to 19.9% of sales last year. Total operating expenses also increased due to higher expenses related to the Company's closure of its King of Prussia facility compared to the prior year period.

Reported operating income for the second quarter of fiscal 2015 increased $1.6 million to $1.2 million, or 6.6% of sales, compared to an operating loss of $0.4 million last year. Reported net income increased $1.2 million to approximately $1.0 million, or $0.04 per diluted share, compared to a loss of $0.2 million, or $0.01 per diluted share, for the same period of fiscal 2014.

As of January 31, 2015, the Company had approximately $8.9 million in cash and $2.75 million in interest-bearing debt. Cash flows provided by operating activities were $4.8 million for the six months ended January 31, 2015, compared to cash flows used by operating activities of $302,000 for the comparable fiscal 2014 period.

Conference Call Information

Synergetics USA, Inc. will host a conference call on Tuesday, March 10, 2015 at 4:00 p.m. Central Time (5:00 p.m. Eastern) to review the Company's results for the fiscal second quarter ended January 31, 2015. The toll free dial-in number to participate live on this call is (800) 588-4973, confirmation code 39067049. For callers outside the U.S., the number is (847) 230-5643. The conference call will also be available live via webcast at http://www.synergeticsusa.com. A replay will be available on the Company's website for approximately 30 days.

Notes to Accompany the Enterprise-wide Sales Table:

(1) Net sales from ophthalmic represent all sales of ophthalmic devices from direct sales representatives, distribution partners and OEMs. Recognition of deferred revenue of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively.

(2) Net sales from neurosurgery represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and certain neurosurgery disposables sold through distribution. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.

(3) Other net sales represent all sales of aesthetic devices, freight and other miscellaneous revenues.

(4) Net sales from ophthalmic represent sales of ophthalmic devices from direct sales representatives and distribution partners.

(5) Net sales from OEM represent sales of electrosurgery generators, disposable bipolar forceps and related accessories and royalties from Codman, multi-channel generators, disposable ultrasonic tips and related accessories to Stryker and sales of certain disposable products. Recognition of deferred revenues of $322,000 and $644,000 from Alcon, Inc. is included in this category for the three and six months ended January 31, 2015 and 2014, respectively. Many of the products that the Company sells to its neurosurgery OEM customers are shipped to their non-U.S. customers in various countries around the world, but are included in the Company's domestic revenues.

(6) Other net sales represent direct neurosurgery revenues and other miscellaneous revenues.

About Synergetics USA, Inc.

Through continuous improvement and development of our people, our mission is to design, manufacture and market innovative surgical devices, capital equipment, accessories and disposables of the highest quality in order to assist and enable surgeons who perform surgery around the world to provide a better quality of life for their patients. 

Synergetics USA, Inc. (the "Company") is a leading supplier of precision surgical devices. The Company's primary focus is on the disciplines of ophthalmology and neurosurgery. Our distribution channels include a combination of direct and independent sales distributor organizations, both domestically and internationally, and important strategic alliances with market leaders. The Company's product lines focus on precision engineered, disposable and reusable devices, surgical equipment, procedural kits and the delivery of various energy modalities for the performance of surgery including: (i) laser energy, (ii) ultrasonic energy, (iii) radio frequency energy for electrosurgery and lesion generation and (iv) visible light energy for illumination, and where applicable, simultaneous infusion (irrigation) of fluids into the operative field. The Company's website address is http://www.synergeticsusa.com.

Use of Non-GAAP Financial Information

The Company measures its performance primarily through its growth in revenue and operating profit. In addition to results reported in accordance with GAAP, the Company provides adjusted operating income and margin, EBITDA and adjusted diluted earnings per share. These adjusted amounts consist of GAAP amounts excluding the adjustment for exit costs occurring during the period. Adjusted earnings per diluted share were calculated by dividing adjusted net income for diluted earnings per share by diluted weighted average shares outstanding. The Company believes that the presentation of adjusted operating income and margin, EBITDA and adjusted diluted earnings per share provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.

These non-GAAP measures are considered by the Company's Board of Directors and management as a basis for measuring and evaluating the Company's overall operating performance and ability to service debt. They are presented to enhance an understanding of the Company's operating results and are not intended to represent cash flow or results of operations.

These non-GAAP measures are not in accordance with, or an alternative to, measures prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with the Company's results of operations as determined in accordance with GAAP. These measures should only be used to evaluate the Company's results of operations in conjunction with the corresponding GAAP measures.

Forward-Looking Statements

Some statements in this release may be "forward-looking statements" for the purposes of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by words such as "believe," "expect," "anticipate," "plan," "potential," "continue" or similar expressions. Such forward-looking statements include risks and uncertainties, and there are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors, risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the year ended July 31, 2014 as updated from time to time in our filings with the Securities and Exchange Commission. The Company is not responsible for updating the information contained in this press release beyond the published date, or for changes made to this document by wire services or Internet services.

 
 
Synergetics USA, Inc. and Subsidiaries
Condensed Consolidated Statements of Income and Comprehensive (Loss) Income (Unaudited)
Three and Six Months Ended January 31, 2015 and 2014
(Dollars in thousands, except share and per share data)
 
  Three Months Ended January 31, 2015     Three Months Ended January 31, 2014     Six Months Ended January 31, 2015     Six Months Ended January 31, 2014
Net sales $ 18,189     $ 15,096     $ 34,836     $ 30,626
Cost of sales   8,605       6,698       15,982       13,304
    Gross profit   9,584       8,398       18,854       17,322
Operating expenses                            
  Research and development   1,028       1,513       2,227       2,710
  Sales and marketing   3,643       3,630       7,339       7,205
  Medical device excise tax   116       115       244       240
  Exit costs   657       514       719       514
  General and administrative   2,942       3,003       5,970       5,638
    8,386       8,775       16,499       16,307
    Operating income (loss)   1,198       (377 )     2,355       1,015
Other income (expense)                            
  Investment income   1       3       2       6
  Interest expense   (14 )     --       (14 )     --
    (13 )     3       (12 )     6
    Income (loss) from operations before provision (benefit) for income taxes  
1,185
     
(374
)    
2,343
     
1,021
Provision (benefit) for income taxes   233       (149 )     623       312
    Net income (loss) $ 952     $ (225 )   $ 1,720     $ 709
Earnings (loss) per share:                            
  Basic earnings (loss) per share $ 0.04     $ (0.01 )   $ 0.07     $ 0.03
  Diluted earnings (loss) per share $ 0.04     $ (0.01 )   $ 0.07     $ 0.03
                             
  Basic weighted average common shares outstanding   25,364,574       25,309,641       25,352,279       25,301,830
  Diluted weighted average common shares outstanding   25,424,835       25,309,641       25,407,508       25,386,679
                             
Net income (loss) $ 952     $ (225 )   $ 1,720     $ 709
Foreign currency translation adjustment   (1,311 )     (35 )     (1,816 )     140
Comprehensive (loss) income $ (359 )   $ (260 )   $ (96 )   $ 849
                             
                             
                             
SYNERGETICS USA, INC. AND SUBSIDIARIES  
Unaudited Table of Net Income and EBITDA  
Three and Six Months Ended January 31, 2015 and 2014  
(In thousands)  
   

EBITDA Reconciliation
  Three Months Ended
January 31, 2015
  Three Months Ended January 31, 2014  
Net income (loss)   $ 952   $ (225 )
Interest expense     14     --  
Income tax provision (benefit)     233     (149 )
Depreciation     380     305  
Amortization     295     186  
EBITDA   $ 1,874   $ 117  
               

EBITDA Reconciliation
  Six Months Ended
January 31, 2015
  Six Months Ended
January 31, 2014
Net income   $ 1,720   $ 709
Interest     14     --
Income tax provision     623     312
Depreciation     689     571
Amortization     543     366
EBITDA   $ 3,589   $ 1,958
             
             
             
SYNERGETICS USA, INC. AND SUBSIDIARIES  
Unaudited Table of Adjusted Operating Income, Operating Margin and Non-GAAP EPS  
Three and Six Months Ended January 31, 2015 and 2014  
(Dollars in thousands, except per share and per share data)  
   

Adjusted Operating Income
  Three Months Ended January 31, 2015     Three Months Ended January 31, 2014     Six Months Ended January 31, 2015     Six Months Ended January 31, 2014  
GAAP Operating Income (Loss)   $ 1,198     $ (377 )   $ 2,355     $ 1,015  
Exit costs     657       514       719       514  
Sterimedix acquisition related costs (1)     204       --       290       --  
Adjusted operating income     2,059       137       3,364       1,529  
Sales     18,189       15,096       34,836       30,626  
Adjusted operating margin     11.3 %     0.9 %     9.7 %     5.0 %
                                 
Non-GAAP EPS Impact                                
                                 
Exit costs   $ 657     $ 514     $ 719     $ 514  
Sterimedix acquisition related costs (1)     204       --       290       --  
Total     861       514       1,009       514  
Effective tax rate     19.7       39.8       26.6       30.6  
Tax effected costs     691       309       741       357  
Diluted weighted average common shares     25,424,835       25,309,641       25,407,508       25,386,679  
Diluted earnings per share   $ 0.03     $ 0.01     $ 0.03     $ 0.01  
                                 
(1) Included in the general and administrative expense line item.
   
   
   
Synergetics USA, Inc. and Subsidiaries  
Condensed Consolidated Balance Sheets  
As of January 31, 2015 (Unaudited) and July 31, 2014  
(Dollars in thousands, except share data)  
   
    January 31, 2015     July 31, 2014  
Assets                
  Current assets                
  Cash and cash equivalents   $ 8,866     $ 15,443  
  Accounts receivable, net of allowance for doubtful accounts of $646 and $722, respectively     13,188       14,641  
  Inventories     16,537       15,134  
  Prepaid expenses     1,075       1,223  
  Deferred income taxes     2,233       2,042  
    Total current assets     41,899       48,483  
Property and equipment, net     10,337       8,785  
Intangible and other assets                
  Goodwill     17,429       12,738  
  Other intangible assets, net     19,574       11,911  
  Deferred income taxes     --       1,219  
  Patents, net     1,415       1,472  
  Deferred financing costs, net     122       --  
  Cash value of life insurance     107       107  
    Total assets   $ 90,833     $ 84,715  
Liabilities and stockholders' equity                
Current liabilities                
  Accounts payable   $ 3,672     $ 2,530  
  Accrued expenses     2,788       2,845  
  Income taxes payable     405       386  
  Contingent acquisition liability     561       --  
  Current maturities of long-term debt     550       --  
  Deferred revenue     1,288       1,288  
    Total current liabilities     9,264       7,049  
Long-Term liabilities                
  Borrowings under term loan facility     2,200       --  
  Deferred income taxes     130       --  
  Contingent acquisition liability     2,000       --  
  Deferred revenue     12,598       13,242  
    Total long-term liabilities     16,928       13,242  
    Total liabilities     26,192       20,291  
Commitments and contingencies                
Stockholders' equity                
  Common stock at January 31, 2015 and July 31, 2014, $0.001 par value, 50,000,000 shares authorized; 25,566,332 and 25,364,608 shares issued and outstanding, respectively     26       25  
  Additional paid-in capital     28,956       28,594  
  Retained earnings     37,880       36,160  
  Accumulated other comprehensive loss:                
  Foreign currency translation adjustment     (2,171 )     (355 )
    Total stockholders' equity     64,691       64,424  
    Total liabilities and stockholders' equity   $ 90,833     $ 84,715  
                     
                     
Synergetics USA Inc. and Subsidiaries  
Consolidated Statements of Cash Flows (Unaudited)  
Six Months Ended January 31, 2015 and 2014  
(Dollars in thousands)  
   
    Six Months Ended
January 31, 2015
    Six Months Ended January 31, 2014  
Cash Flows from Operating Activities                
  Net income   $ 1,720     $ 709  
  Adjustments to reconcile net income to net cash provided by (used in) operating activities                
    Depreciation     689       571  
    Amortization     543       366  
    Provision for doubtful accounts receivable     8       6  
    Stock-based compensation     388       605  
    Deferred income taxes     (67 )     (35 )
Changes in assets and liabilities                
  Decrease (increase) in:                
    Accounts receivable     1,638       1,164  
    Inventories     (36 )     (1,854 )
    Prepaid expenses     177       (254 )
    Income taxes refundable     --       254  
  Increase (decrease) in:                
    Accounts payable     730       (213 )
    Accrued expenses     (243 )     (940 )
    Deferred revenue     (644 )     (644 )
    Income taxes payable     (120 )     (37 )
      Net cash provided by (used in) operating activities     4,783       (302 )
                 
Cash Flows from Investing Activities                
  Purchase of property and equipment     (393 )     (735 )
  Acquisition of Sterimedix     (13,177 )     --  
  Acquisition of patents and other intangibles     (69 )     (139 )
      Net cash used in investing activities     (13,639 )     (874 )
                 
Cash Flows from Financing Activities                
  Deferred financing costs     (123 )     --  
  Proceeds from borrowings under the Revolving Credit Line     2,750       --  
  Proceeds from the issuance of common stock     28       36  
  Tax benefit associated with the exercise of non-qualified stock options     16       25  
      Net cash provided by financing activities     2,671       61  
                 
Foreign exchange rate effect on cash and cash equivalents     (392 )     (133 )
Net decrease in cash and cash equivalents     (6,577 )     (1,248 )
Cash and cash equivalents                
  Beginning     15,443       12,470  
  Ending   $ 8,866     $ 11,222  
                 

Contact Information

  • SYNERGETICS USA, INC.
    3845 Corporate Centre Drive
    O'Fallon, Missouri 63368
    (636) 939-5100
    http://www.synergeticsusa.com
    Pamela G. Boone
    Chief Financial Officer